Last updated on July 2018

Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis


Brief description of study

This is a multi-center, randomized, vehicle controlled, double-blind Phase 2 study in pediatric patients age 2-17 years old with mild to moderate atopic dermatitis.

Detailed Study Description

The purpose of this study is to evaluate the safety, efficacy, and tolerability of a 0.5% BID concentration of RVT-501 in pediatric patients 2-17 years of age with mild to moderate atopic dermatitis. The pharmacokinetics of RVT-501 will also be evaluated in patients 2-11 years of age.

Clinical Study Identifier: NCT03394677

Contact Investigators or Research Sites near you

Start Over

Dermavant Clinical Trials

Dermavant Investigational Site
Los Angeles, CA United States

Dermavant Clinical Trials

Dermavant Investigational Site
Oklahoma City, OK United States

Dermavant Clinical Trials

Dermavant Investigational Site
Portland, OR United States

Dermavant Clinical Trials

Dermavant Investigational Site
Dallas, TX United States

Dermavant Clinical Trials

Dermavant Investigational Site
San Antonio, TX United States

Dermavant Clinical Trials

Dermavant Investigational Site
Surrey, BC Canada

Dermavant Clinical Trials

Dermavant Investigational Site
Montreal, QC Canada